Abstract
Improving our knowledge of the development, course and treatment of major depression is among the most pressing public health concerns in medicine. It is therefore satisfying to observe that critical advances have been made in our fundamental understanding of this illness and related conditions in the past several years. Among the areas of major change have been advances in nosology and disease classification, an improved understanding of risk factors for the development of major depression, advances in the standards of clinical practice, enhanced societal acceptance of patients with the disease and their treatment, and a substantial increase in our understanding of the underlying neurobiology of this common, disabling, and potentially lethal illness. It is sobering, in contrast, to observe that we still use methods of clinical study to explore new treatments with this condition that employ study designs and measurement tools which have changed very little over the past three decades. In this selective review, several key areas of interest relevant to the clinical development of antidepressants are examined. These areas point to some suggested topics for attention in the future.
Keywords: major depression, antidepressants, rating scales, diagnosis, clinical trials, methodology
Current Pharmaceutical Design
Title: Clinical Perspectives on Antidepressant Drug Development: A Critical Discussion
Volume: 11 Issue: 2
Author(s): M. A. Demitrack
Affiliation:
Keywords: major depression, antidepressants, rating scales, diagnosis, clinical trials, methodology
Abstract: Improving our knowledge of the development, course and treatment of major depression is among the most pressing public health concerns in medicine. It is therefore satisfying to observe that critical advances have been made in our fundamental understanding of this illness and related conditions in the past several years. Among the areas of major change have been advances in nosology and disease classification, an improved understanding of risk factors for the development of major depression, advances in the standards of clinical practice, enhanced societal acceptance of patients with the disease and their treatment, and a substantial increase in our understanding of the underlying neurobiology of this common, disabling, and potentially lethal illness. It is sobering, in contrast, to observe that we still use methods of clinical study to explore new treatments with this condition that employ study designs and measurement tools which have changed very little over the past three decades. In this selective review, several key areas of interest relevant to the clinical development of antidepressants are examined. These areas point to some suggested topics for attention in the future.
Export Options
About this article
Cite this article as:
Demitrack A. M., Clinical Perspectives on Antidepressant Drug Development: A Critical Discussion, Current Pharmaceutical Design 2005; 11 (2) . https://dx.doi.org/10.2174/1381612053382296
DOI https://dx.doi.org/10.2174/1381612053382296 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
GDF 15 - A Novel Biomarker in the Offing for Heart Failure
Current Cardiology Reviews Wave Intensity Analysis in the Human Coronary Circulation in Health and Disease
Current Cardiology Reviews The Serpin Solution; Targeting Thrombotic and Thrombolytic Serine Proteases in Inflammation
Cardiovascular & Hematological Disorders-Drug Targets The Stress Response: Implications for the Clinical Development of Hsp90 Inhibitors
Current Cancer Drug Targets Novel Insights Into Lp(a) Physiology and Pathogenicity: More Questions Than Answers?
Cardiovascular & Hematological Disorders-Drug Targets Preface [Hot topic: Antithrombotic Agents Executive Editor : Ho-Sam Ahn ]
Current Pharmaceutical Design Circulating Biomarkers for the Diagnosis and Prognosis of Heart Failure
Current Medicinal Chemistry Human Endotoxemia as a Model of Systemic Inflammation
Current Medicinal Chemistry The Mechanism of Carvedilol in Experimental Viral Myocarditis
Current Pharmaceutical Design Why are People with “Poor Lung Function” At Increased Atherothrombotic Risk?A Critical Review with Potential Therapeutic Indications
Current Vascular Pharmacology Editorial: Understanding Basic Muscle Electrophysiology While Keeping an Eye on Diseases of the Heart, Lung and Blood
Recent Patents on Cardiovascular Drug Discovery Oxidative stress and myocarditis
Current Pharmaceutical Design Severe Neutropenia in a Renal Transplant Patient Suggesting an Interaction Between Mycophenolate and Fenofibrate
Current Drug Safety How Effective are the Lipid Modifying Medicines at Preventing Coronary Heart Disease in Patients with Type 2 Diabetes?
Vascular Disease Prevention (Discontinued) Vitamin D Biology in Heart Failure: Molecular Mechanisms and Systematic Review
Current Drug Targets Prevention of Respiratory Syncytial Virus: A Review
Current Respiratory Medicine Reviews Dietary Carbohydrates - Requirement and Recommendation in the Human Diet
Current Nutrition & Food Science Overview and Developments Regarding Functional Foods and Beverages
Current Nutrition & Food Science Humoral Immunity in Heart Failure
Cardiovascular & Hematological Disorders-Drug Targets Management of COVID-19 very Elderly Patients in Nursing Homes and Long-Term Care Facilities: Description of a New Model and Experience in a Medicalized Nursing Home
Coronaviruses